เดือน: มิถุนายน 2025

TOKYO, June 3, 2025 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station is an anime exhibition site focused on Japanese anime content, which has developed a devoted fan base around the world. It attracts 167,410 visitors (as of May 18, 2025), children and adults alike, from both Japan and overseas. We are pleased to announce the launch of the official Anime Tokyo Station YouTube channel, along with the release of a new promotional video narrated by renowned voice actor Akio Otsuka, introducing the facility.Promotional video narrated by Akio OtsukaAs you wander freely through the interior spaces of Anime Tokyo Station, you’ll encounter striking symbolic displays, special exhibitions that showcase the appeal of Japanese anime, archived materials, and a variety of services on each floor. Enjoy a leisurely tour of the facility with narration by renowned voice actor Akio Otsuka.Going forward, the official Anime Tokyo Station YouTube channel will regularly share new videos, including further introductions to the facility, as well as coverage of special exhibitions, workshops, and events. The channel aims to serve as a hub for anime exhibitions and keep viewers informed about Anime Tokyo Station’s ongoing initiatives.YouTube overviewChannel name: Anime Tokyo Station Official ChannelChannel URL: https://www.youtube.com/channel/UCSJOjGJE5Yiqw3PZ97AVdJwFacility Introduction Video: https://www.youtube.com/watch?v=1jp-OK_Kfe8Venue Overview- Name: Anime Tokyo Station (also known as "Anime Tokyo")- Location: Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from the East Exit of Ikebukuro Station- Hours: 11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m.)- Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.- Admission fee: Free- Website: https://animetokyo.jp/en/ Inquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jpPress release: https://www.acnnewswire.com/docs/files/20250603.pdf  Copyright 2025 JCN Newswire via SeaPRwire.com.

Strasbourg, France & Tokyo, Japan, June 2, 2025 - (JCN Newswire via SeaPRwire.com) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, have presented new positive data on TG4050 in a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.These positive data confirm that individualized neoantigen therapeutic vaccine TG4050 is safe and feasible in the adjuvant setting of resectable HPV-negative locally advanced head and neck squamous cell carcinoma (HNSCC). TG4050 induces, as monotherapy, long-lasting immune responses to vaccine neoantigens sustained for up to 2 years, and these results met all trial endpoints (NCT04183166) including safety, feasibility, immune activation and disease-free survival (defined as survival without recurrence or death for any cause).TG4050 is based on Transgene’s myvac® platform and powered by NEC’s cutting-edge AI capabilities designed to optimize antigen selection.Positive data from Phase I, confirming proof of principle of Transgene’s viral vector based individualized cancer vaccine TG4050 in HPV-negative locally advanced head and neck cancer 100% disease free survival at a minimum of 2-year follow-up of treated patients (median follow-up: 30 months) in the Phase I part of the trial: all patients in the TG4050 treatment arm remain disease free while 3 patients in the observational arm have relapsed.Persistence of neoantigen-specific CD8+ T cell responses over 2 years after the start of TG4050 has been observed.Dr. Alessandro Riva, CEO of Transgene, commented: "The sustained clinical and immunogenicity outcomes observed over two years of TG4050 monotherapy, along with the positive safety profile, mark an important milestone for Transgene. These results reinforce both the clinical promise of TG4050 and our commitment to accelerate the development of this individualized immunotherapy in adjuvant setting for patients with HPV-negative, locally advanced head and neck cancer."Motoo Nishihara, Corporate EVP and CTO at NEC, commented: "This positive readout, combined with the durability of the efficacy data at two years, underscore the clinical potential of individualized cancer vaccine programs. It is a strong validation of our innovative AI platform and our dedication to advancing solutions that deliver meaningful, long-term value to patients and healthcare systems alike."Ongoing Phase II part of Phase I/II clinical trial of individualized neoantigen therapeutic cancer vaccine TG4050TG4050 is being evaluated in a randomized multicenter Phase I/II trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166). Based on the promising data obtained in the Phase I part of the trial, Transgene and NEC extended the joint development of TG4050 in this indication with a Phase II extension of the trial.The Phase II part of the trial, aimed at confirming the encouraging results in a larger patient population and evaluating both immunological and clinical outcomes, is currently underway. All patients are expected to be randomized by Q4 2025. Altogether, the Phase I/II study will comprise approximately 80 patients.A conference call in English is scheduled June 6, 2025, at 3:00 p.m. CET. (9:00 a.m. ET)Webcast link to English language conference call: https://edge.media-server.com/mmc/p/x49uzc62 Please log in to the following link to obtain your personal telephone IDs: https://register-conf.media-server.com/register/BId8c981041ca84dad92bb2faa73fc5344 A replay of the call will be available on the Transgene website (www.transgene.com) following the live event.About TransgeneTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company’s lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities.With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.Additional information about Transgene is available at: www.transgene.com  Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @TransgeneAbout myvac®myvac® is a viral vector (MVA – Modified Vaccinia Ankara) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac®-derived products are designed to stimulate the patient’s immune system to recognize and destroy tumors using their own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded "Investment for the Future" funding from Bpifrance for the development of its platform myvac®. TG4050 is the first myvac®-derived product being evaluated in clinical trials. Click here to watch a short video on myvac.About TG4050TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s myvac® technology and powered by NEC’s longstanding artificial intelligence (AI) and machine learning (ML) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC’s Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic sequences.TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed and produced for each patient.About the Phase I/II clinical trialTG4050 is being evaluated in a Phase I/II clinical trial for patients with HPV-negative head and neck cancers (NCT04183166). An individualized treatment is created for each patient after they complete surgery and while they receive adjuvant therapy. Half of the participants received their vaccine immediately after completing adjuvant treatment. The other half were given TG4050 as an additional treatment at the time of recurrence of the disease as an additional treatment to standard of care (SoC). This randomized study is evaluating the treatment benefits of TG4050 in patients who are at risk of relapse. In the Phase I part, thirty-two evaluable patients have been included. The Phase II part is currently enrolling patients internationally.About NEC’s Neoantigen Prediction SystemNEC’s neoantigen prediction system utilizes its proprietary AI, such as graph-based relational learning, trained on multiple sources of biological data to discover candidate neoantigen targets. These targets are carefully analyzed using proprietary machine learning algorithms that include in-house HLA binding and antigen presentation AI tools to evaluate the likelihood of eliciting a robust and clinically relevant T-cell response. With NEC OncoImmunity now on board, NEC continues to strengthen its top-class neoantigen prediction pipelines with the aim of maximizing the therapeutic benefits of personalized cancer immunotherapy for patients worldwide.For more information, please visit NEC Bio at https://www.nec-bio.com or https://www.nec-bio.com/en_DD/research-and-innovation/our-approach/ About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential.For more information, visit NEC at https://www.nec.com. DisclaimerThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (https://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, June 2, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. announced today the launch of “Pariet®S” (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan.(1)"Pariet S" is the first proton pump inhibitor (PPI(2)) to receive manufacturing and marketing approval as an over the counter (OTC) medicine in Japan. Rabeprazole sodium, in an amount equivalent to that used in the prescription product(3), works directly on the proton pumps that produce stomach acid, effectively alleviating severe heartburn caused by gastric acid reflux and stomach pain due to excessiveacid secretion. The medicine comes in small, easy-to-swallow tablets, with a once-daily dosage providing 24-hour relief.Rabeprazole sodium, the active ingredient in “Pariet S”, is a PPI developed at Eisai’s Tsukuba Research Laboratories. The medicine was first launched in Japan in 1997 as a prescription pharmaceutical underthe brand name “Pariet” and has since been approved more than 100 countries worldwide. It is widely prescribed to people struggling with acid-related disorders.In recent years, there is a tendency for increased stomach acid secretion due to disrupted eating habits, stress, and a decline in the infection rate of Helicobacter pylori. Moreover, the number of individuals experiencing gastric acid reflux has grown, driven by age-related weakening of the lower esophageal sphincter. Eisai will introduce “Pariet S” as a new treatment option in the OTC gastric medication market, aiming to alleviate sever heartburn and discomfort caused by gastric acid related conditions, and strongly support people in the daily living domain who wish for a comfortable and secure daily life.For further details, please refer to the product’s website for details about "Pariet S" (Japanese only) https://www.eisai.jp/products/pariet/pariets(1) "Pariet S" is classified as a drug that requires a pharmacist’s guidance at the time of sale(2) Proton Pump Inhibitor suppresses gastric acid secretion by inhibiting the “proton pump” which is the final step in the secretion process.(3) Contains rabeprazole10mg per tabletMedia Inquiries:Public Relations DepartmentEisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, June 2, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Corporation (“MC”) has agreed to acquire shares in DEScycle Ltd., a company known for its innovative technology in metal recovery from e-scrap. The two companies will also enter into a strategic business partnership to foster collaboration.E-scrap contains valuable materials such as copper and precious metals, and its value as an urban mine has grown in recent years. With the continued integration of AI into society, the rapid expansion of data centers is expected to increase the volume of e-scrap. However, due to the challenges of achieving clean and cost-effective recycling, a large portion of e-scrap is still disposed of in landfills, raising serious environmental concerns.DEScycle's proprietary technology* enables to selectively dissolve metals at room temperature and atmospheric pressure, and is expected recover metals with significantly lower energy consumption and environmental impact compared to conventional smelting methods. By effectively utilizing e-scrap as a secondary resource, it contributes to sustainable resource circulation.The funds raised by DEScycle will support the construction and operation of a pilot plant in the UK. Following the demonstration phase, a commercial-scale plant with an annual processing capacity of approximately 5,000 tons is scheduled to begin operations in the UK in 2028, with plans to further expand to North America, Japan, and other regions.MC will leverage its trading expertise and industry network to undertake marketing activities for metal products such as copper and precious metals derived from e-scrap using DEScycle's technology. Additionally, MC will utilize its investment expertise to explore the expansion of the business together with DEScycle, aiming to contribute to the realization of a circular economy.*Proprietary technology developed by DEScycle uses Deep Eutectic Solvents (DES) to selectively dissolve metals at room temperature and atmospheric pressure.DEScycleDEScycle is a deep technology company developing disruptive metals processing technologies utilising a novel and eco-friendly class of chemistry known as DES. DES are recyclable liquid salts that allow for low-temperature, low-energy operations; resulting in low-carbon, low-impact metals. DEScycle’s technology can end the reliance upon high-energy pollutive processes like smelting and the use of highly toxic chemicals in the metals industry.Initially focused on the $100bn e-waste market, DEScycle’s mission is to commercialise a clearly differentiated recycling technology with industry leading costs, performance, environmental impact and transparency.About Mitsubishi CorporationMitsubishi Corporation is a global integrated business enterprise that develops and operates business together with its offices and subsidiaries worldwide. MC has eight Business Groups that operate across virtually every industry: Environmental Energy, Material Solution, Mineral Resources, Urban Development and Infrastructure, Mobility, Food Industry, Smart-Life Creation, and Power Solution.Inquiry RecipientMitsubishi CorporationTelephone:+81-3-3210-2171 Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, June 2, 2025 - (JCN Newswire via SeaPRwire.com) - JCB Co., Ltd., Japan's only global payment brand, is proud to announce that its exclusive cardmember mobile app, the MyJCB App, has been honored with the Gold Award in the Mobile Technologies, Applications, and Software Design category at the A' Design Award & Competition.This recognition follows the app’s recent success at the iF DESIGN AWARD 2025, making yet another significant milestone for the MyJCB App. The Gold Award is bestowed upon designs that place within the top 3% of all submissions, reflecting an exceptional standard of design excellence.The app’s service design and UI/UX design were developed in collaboration with FOURDIGIT Inc.Design Approach Focused on User ExperienceSince 2021, JCB has been collaborating with FOURDIGIT to enhance the MyJCB App through a comprehensive approach encompassing service design, UI/UX design, and the implementation of continuous improvement processes.As part of the renewal project, the team developed a strategy to define the app's role within the overall service experience, based on a detailed analysis of user behavior and challenges. They conducted surveys with thousands of users and in-depth interviews with over 50 participants to thoroughly examine credit card usage patterns and customer needs across various service channels, ultimately creating a comprehensive vision for cross-channel user experience.Following the renewal, the team has continued to enhance the app by leveraging app store feedback, user interviews, and usage data analysis, with the  aim of creating an app that serves all customers, regardless of their level of financial literacy. They remain committed to delivering safer and more convenient card services while actively listening to customer feedback.For more information, please visit: https://www.4digit.com/en/projects/myjcbAbout MyJCB AppMyJCB is a web service exclusively for JCB cardmembers, offering features such as transaction history viewing, point balance checking, and security alert notifications. Launched in 2016, the MyJCB App underwent a significant renewal in November 2023 under the concept of "Card and App Integration." This renewal introduced enhanced visibility and accessibility, along with strengthened security features that reflect JCB's core value of customer safety and security—transforming the app into a more convenient and secure tool for cardmembers.The app enables users to sort transaction details by amount or date and features a keyword search function for seamless navigation. Its security features include "Card Usage Notifications" and "Security Status Recommendations," which suggest optimal security settings to support safe card usage.Continuously evolving through regular updates and feature enhancements, the app is designed to meet the diverse needs of all cardmembers, including digital concierge services for THE CLASS and Platinum cardmembers, as well as customizable app themes featuring four design options.For more information about the MyJCB App: https://www.jcb.co.jp/myjcb/app/index.htmlFor details about the Digital Concierge feature:https://www.jcb.co.jp/promotion/digital_concierge/index.htmlAbout A’ Design Award & CompetitionA' Design Award and Competition is one of the world’s largest, most prestigious and influential design accolades, one of the highest achievements in design. Entries are evaluated by an internationally influential jury panel composed of established scholars, prominent press members, creative design professionals, and experienced entrepreneurs. In the 2024–2025 edition, 1,821 winners from 115 countries were selected.Award summaryCategory: Mobile Technologies, Applications and Software DesignAward: Golden A' Design Awardhttps://competition.adesignaward.com/167269About JCB and FOURDIGITJCB Co., Ltd.JCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 56 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 169 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide.For more information, please visit: www.global.jcb/en/FOURDIGIT Inc.FOURDIGIT is a design and tech company that provides essential 'design' to connect digital technology and people, creating comfortable experiences for everyone involved. Drawing on our expertise cultivated in Japan, we are expanding our services to regions across Asia where the demand for digital design is growing alongside economic development. Our objective is to deliver design and technology solutions that drive business success on a global scale. Our current office locations include Japan, Thailand, Vietnam, and Malaysia. Copyright 2025 JCN Newswire via SeaPRwire.com.

KAWASAKI, Japan, June 2, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced its collaboration with Kawasaki City to launch a redevelopment project for the Fujitsu Technology Park in anticipation of its 90th anniversary in June 2025.Envisioned as an "Open Innovation & Technology Park," this initiative will foster connections between diverse stakeholders including – local government, the community, research institutions, and educational organizations – to cultivate an open environment where materiality initiatives and innovation can flourish. Building upon the spirit of Fujitsu's founding, the Fujitsu Technology Park will see a phased expansion, incorporating cutting-edge technology demonstration zones, environmental sustainability initiatives, and enhanced sports and wellness experiences. Fujitsu will promote this redevelopment with the aim of completion by 2035, coinciding with Fujitsu's centennial celebration.Redevelopment project overviewFujitsu initially embarked on a redevelopment plan in 2011 to elevate the Kawasaki Office (now Fujitsu Technology Park), a cornerstone of the company since its inception, into a world-class research and development campus. While this plan was temporarily paused for review in 2015, the demolition of outdated structures is currently underway.In the intervening years, Fujitsu has actively championed Kawasaki City's vision for a sustainable urban future, strengthening its partnership with the city. As a key milestone, in the first half of fiscal year 2024, Fujitsu consolidated its research and development         departments and corporate functions into Fujitsu Technology Park and relocated its headquarters functions there. Furthermore, in January 2025, Fujitsu commenced the construction of a state-of-the-art, quantum computing facility as part of our research and development strategy for quantum computing. This facility will house one of the world's most powerful superconducting quantum computers, boasting 1,000 qubits, and is projected to be completed in fiscal year 2026.Redevelopment project conceptThe "Open Innovation & Technology Park" concept will be realized through phased redevelopment following the four distinct themes listed below.The overarching goal is to create an accessible, community-integrated, and walkable space.・Cultivation of a rich and sustainable environmentFujitsu aims to spearhead regional sustainability by implementing multifaceted initiatives, including promoting harmony with nature, conserving biodiversity, and creating green spaces to enhance resilience. The goal is for these initiatives to have a ripple effect throughout the region.・Connecting society through technology and innovationFujitsu is committed to collaborating with the local community to drive innovation, accelerate its social implementation, and enhance daily life.・Promotion of holistic well-being through sports and healthBy leveraging technology and data, Fujitsu seeks to create novel and engaging experiences centered on health and sports, contributing to overall well-being.・Honoring the founding spirit of innovationFujitsu will honor its founding spirit, deeply rooted in Kawasaki City, by accelerating materiality initiatives. This will be achieved by fostering connections between the Fujitsu Group, government agencies, and the local community through the Fujitsu Technology Park's redevelopment.Future plansA dedicated Fujitsu Sports zone will be established in the northwest corner of the site, featuring a newly constructed gymnasium, the Fujitsu Arena. By harnessing the power of technology and data, this area will provide engaging and novel sports experiences for all. The multi-purpose facility will also serve as a venue for company events and a temporary evacuation center for local residents in the event of a disaster.Step 2: Fujitsu Museum/Open Innovation (tentative name)As the gateway to the Fujitsu Technology Park, a multi-purpose facility will be constructed to connect customers, the community, and society with Fujitsu. The project also includes the development of a plaza near the station. This facility will house the Fujitsu Museum and serve as a welcoming space where people can gather, explore technology, ignite their creativity, and contribute to future innovations.Subsequent redevelopment phases after Step 1, Step 2 will be shared in due course, considering evolving circumstances and following consultations with stakeholders, including local residents.Fujitsu’s Commitment to the Sustainable Development Goals (SDGs)The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030.Fujitsu’s purpose — “to make the world more sustainable by building trust in society through innovation” — is a promise to contribute to the vision of a better future empowered by the SDGs.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2025 JCN Newswire via SeaPRwire.com.